Supporting Information: Fig. S2




Fig. S2. Biodistribution and therapeutic results of α -RIT using ²¹¹At-trastuzumab in the subcutaneous xenograft mouse models. (a) Biodistribution of ²¹¹At-trastuzumab in mice with a subcutaneous xenograft of N87. Uptakes (%ID/g) of ²¹¹At in the tumor and other

organs at 1, 3, 6, 12, and 24 h after i.v. injection of ²¹¹At-trastuzumab (0.5 MBq). Four mice were used at each time point. Mean \pm SD. (b) Relative tumor volume in each mouse enrolled in this study. The tumor volume before the treatment was considered 100%. Six mice were enrolled in each of the treatment groups except in the trastuzumab group (seven mice). PBS (Control). Mean \pm SD (P < 0.05, *vs. Control, †vs. Tras.). (c) Kaplan-Meier survival curves of mice (P < 0.05, *vs. Control, †vs. Tras.). (d) Body weights of mice after treatment. (e) Numbers of white blood cells of the mice after treatment. Plots in (b), (d), and (e) were interrupted when any mouse enrolled in a group reached the endpoint. Data in (d) and (e) are presented as the mean \pm SD.